This is a Phase II grant application to further develop long acting G-CSF proteins for the treatment of neutropenia. It is submitted by Bolder Biotechnology, Inc. George N. Cox, PhD, Principal investigator. The investigator notes the recombinant G-CSF has a worldwide sales in excess of $1.2 Billion in 1998. They propose to create modified G-CSF proteins that are equal to or superior than natural G-CSF in stimulating granulocyte formation in-vivo but would require less frequent dosing. Their goal is to have a long acting protein that could be given once a week or every other week. During Phase I they identified sites in the G-CSF that could be modified without reducing the proteins bio-activity in-vitro. During Phase II they plan to manufacture sufficient quantities of the modified G-CSF protein for testing in animal models with neutropenia. It is their contention that these novel G-CSF proteins will reduce the amount of G-CSF required per patient, improve patient compliance and quality of life, and result in considerable cost savings for patients and healthcare providers.

Proposed Commercial Applications

Not Available

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44CA078094-02
Application #
6208976
Study Section
Special Emphasis Panel (ZRG1-HEM-1 (01))
Program Officer
Muszynski, Karen
Project Start
1999-01-01
Project End
2003-02-28
Budget Start
2001-03-01
Budget End
2002-02-28
Support Year
2
Fiscal Year
2001
Total Cost
$403,950
Indirect Cost
Name
Bolder Biotechnology, Inc.
Department
Type
DUNS #
City
Boulder
State
CO
Country
United States
Zip Code
80301